Skip to main content

Table 5 Member States of the WHO European region reporting on surveillance-related activities by EU/EEA membership

From: Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014)

 

EU/EEA

non-EU/EEA

 
 

N = 25

%

N = 19

%

p-value

National coordination

     

 Existence of a written national strategy or plan that focuses exclusively or primarily on the prevention and control of viral hepatitis and includes a surveillance component

6

24.0

6

31.6

0.412

Routine surveillance of viral hepatitis B and C

     

 National surveillance system for acute HBV

25

100

18

94.7

0.432

 National surveillance system for acute HCV

23

92.0

18

94.7

0.604

 National surveillance system for chronic HBV

18

72.0

10

52.6

0.157

 National surveillance system for chronic HCV

17

68.0

10

52.6

0.234

 Standard case definitions for viral hepatitis infections

25

100

17

89.5

0.181

 Regular hepatitis disease reports published

22

88.0

17

89.5

0.632

 Hepatitis outbreaks required to be reported to the government and further investigated

23

92.0

19

100

0.317

 Adequate laboratory capacity nationally to support hepatitis outbreak investigations and other surveillance activities for HBV and HBC

25

100

19

100

-

Other sources of strategic information and capacities for disease burden estimation

     

 Deaths, including from hepatitis, reported to a central registry

25

100

17

89.5

0.181

 Liver cancer cases registered nationally

22

88.0

13

68.4

0.122

 Cases of HIV/hepatitis co-infection registered nationally

16

64.0

13

68.4

0.508

 Viral hepatitis serosurveys conducted regularly

10

40.0

10

52.6

0.299

  If yes, please specify the target populations:

     

   - children

3

12.0

2

10.5

0.632

   - general population

8

32.0

3

15.8

0.191

   - people who inject drugs

6

24.0

6

31.6

0.412

   - men who have sex with men

3

12.0

6

31.6

0.112

   - other groups

7

28.0

10

52.6

0.089

 All pregnant women screened for HBV

21

84.0

13

68.3

0.195

 All donated blood (including family donations) screened for HBV

25

100

17a

94.4

0.419

 All donated blood (including family donations) screened for HCV

25

100

18a

100

0.432

Areas in which Member States might want assistance from WHO

     

 National plan

6

24.0

11

57.9

0.024

 Surveillance

2

8.0

8

42.1

0.010

 Burden estimation

6

24.0

9

47.4

0.097

  1. aAndorra is not included in this calculation because Andorra does not have blood donation centres